Patents by Inventor Gregory A. Lazar

Gregory A. Lazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED Fc VARIANTS
    Publication number: 20240026023
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 11820830
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20220348634
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 3, 2022
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Heterodimeric Fc variants
    Patent number: 11401348
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 2, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Gregory Moore
  • CTLA4-IG immunoadhesins
    Patent number: 11352412
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • CTLA4-Ig immunoadhesins
    Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • MODIFIED ANTIBODY FCS AND METHODS OF USE
    Publication number: 20220033520
    Abstract: Biological macromolecules have tremendous potential for the treatment of disease of the central nervous system (CNS), however, the presence of the blood brain barrier (BBB) makes achieving a therapeutically relevant antibody concentration extremely challenging. Antibodies with enhanced neutral pH affinity for the neonatal Fc receptor demonstrate improved accumulation in the brain. Variants disclosed herein also enhanced exposure in engineered mouse models. Using an anti-BACE1 antibody, these Fc variants significantly reduced the levels of brain Abeta.
    Type: Application
    Filed: June 9, 2021
    Publication date: February 3, 2022
    Applicant: Genentech, Inc.
    Inventors: Gregory A. Lazar, James Ernst, Jasvinder Atwal, Shraddha Shirish Sadekar, Yanli Yang, Shan Chung
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 11098129
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20210230250
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • ANTIGEN BINDING COMPLEX HAVING AGONISTIC ACTIVITY AND METHODS OF USE
    Publication number: 20210147562
    Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
    Type: Application
    Filed: October 27, 2020
    Publication date: May 20, 2021
    Applicant: Genentech, Inc.
    Inventors: Gregory LAZAR, Jeong KIM, Jing ZHU, Yanli YANG, Randall BREZSKI
  • Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
    Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • OPTIMIZED Fc VARIANTS
    Publication number: 20210139600
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 29, 2020
    Publication date: May 13, 2021
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210115147
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: August 4, 2020
    Publication date: April 22, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John Desjarlais, Sher Bahadur Karki, Gregory Lazar
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20210087288
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: September 1, 2020
    Publication date: March 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 10808036
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 20, 2020
    Assignee: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
    Publication number: 20200123274
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Application
    Filed: August 13, 2019
    Publication date: April 23, 2020
    Inventors: Gregory Lazar, Gregory Moore
  • Anti-Transferrin Receptor Antibodies and Methods of Use
    Publication number: 20200123267
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Fc variants with increased affinity for Fc?RIIc
    Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 10508151
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: December 17, 2019
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20190127437
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 2, 2019
    Inventors: Gregory A. Lazar, Matthew J. Bernett